Age-related brain insulin abnormalities are a cause of cognitive decline, including dementia and Alzheimer’s disease.

The therapy combined two drugs: harmine, a natural molecule found in certain plants that inhibits an enzyme called DYRK1A ...

Results from early clinical trials suggest that liraglutide, a GLP-1 drugs, may help protect the brain against cognitive ...

The results of the new study could have significant implications for understanding diabetes / publication in ‘Molecular Metabolism’ ...

Weight loss drugs are here to stay. Pharmaceuticals, insurance companies, and consumer staples companies are all grappling ...

Risk reduced for 10 of 13 obesity-associated cancers with GLP-1 RA use versus insulin in individuals with type 2 diabetes.

and insulin-sensitizing benefits. Researchers highlight the unprecedented success of GLP-1-based multi-receptor drugs in achieving substantial weight loss and improved health outcomes, potentially ...

Researchers reviewed studies on dietary impacts of GLP-1 and GIP/GLP-1 receptor agonists in obesity and T2D patients, finding ...

A recent study suggests that a GLP-1 drug, liraglutide, may protect the brains of people with mild Alzheimer’s disease, ...

Along with weight loss and cardiovascular benefits, GLP-1 RA drugs may reduce the risks of some obesity-related cancers.

TUESDAY, July 30, 2024 (HealthDay News) -- Smokers with diabetes or obesity who take semaglutide (Ozempic/Wegovy) might reap ...

New clinical trial data suggest promising therapeutic effects of the GLP-1 liraglutide on cognition and brain size in ...